(Total Views: 720)
Posted On: 07/05/2020 4:24:25 PM
Post# of 148908
I think I agree that its probably true that Patterson is free to expound upon his theory as he likes, unrestricted in any way by the FDA.
What I wonder is: If Patterson knows the primary outcome of the S/C trial, then is he free to publicize its result without restriction by the FDA?
I am assuming that Patterson is doing full blood work at 0,2,7,14,28 days on each and every patient in the S/C trial. Yesterday Pourhassan confirmed that Patterson is doing at least some work on some patients, so this is certainly a dubious assumption.
My proposition is that if Patterson has come to know the pirmary outcome of the S/C trial by his routine work in due course of the trial, is he allowed to publicize the facts that he has observed, which would be a running day-by-day tally of deaths in placebo vs. leronlimab arms?
Whether Patterson can theorize based on the day-by-day tally of placebo vs. leronlimab deaths is also important, but I wonder if Patterson can just blurt out the day-by-day tally of leronlimab vs. placebo. If he can do it for one day, then he can do it for every day.
If Patterson gets all the blood work, he knows with 100% certainty from the receptor occupancy test whether the patient is placebo or leronlimab.
Perhaps the real story as to when trial data will be released is as others have predicted: Cytodyne, Samsung, the FDA, and the federal government will make a group effort to release information simultaneously as they all have common interests.
What I wonder is: If Patterson knows the primary outcome of the S/C trial, then is he free to publicize its result without restriction by the FDA?
I am assuming that Patterson is doing full blood work at 0,2,7,14,28 days on each and every patient in the S/C trial. Yesterday Pourhassan confirmed that Patterson is doing at least some work on some patients, so this is certainly a dubious assumption.
My proposition is that if Patterson has come to know the pirmary outcome of the S/C trial by his routine work in due course of the trial, is he allowed to publicize the facts that he has observed, which would be a running day-by-day tally of deaths in placebo vs. leronlimab arms?
Whether Patterson can theorize based on the day-by-day tally of placebo vs. leronlimab deaths is also important, but I wonder if Patterson can just blurt out the day-by-day tally of leronlimab vs. placebo. If he can do it for one day, then he can do it for every day.
If Patterson gets all the blood work, he knows with 100% certainty from the receptor occupancy test whether the patient is placebo or leronlimab.
Perhaps the real story as to when trial data will be released is as others have predicted: Cytodyne, Samsung, the FDA, and the federal government will make a group effort to release information simultaneously as they all have common interests.
(4)
(0)Scroll down for more posts ▼
